Abbott (NYSE:ABT) today announced results from 3 clinical studies of focal impulse rotor modulation guided rotor ablation for treating atrial fibrillation using the company’s RhythmView technology, touting high rates of freedom from AF. Results from the investigator-sponsored studies, which explored the benefits of FIRM-guided rotor ablation combined with traditional AF care, were presented at Cardiostim-EHRA […]
Abbott
Abbott touts clinical trial of its wearable glucose monitor at ADA
Abbott (NYSE:ABT) touted clinical trial results of its wearable Freestyle Libre glucose monitor at the annual meeting of the American Diabetes Association in New Orleans. Compared to users of conventional blood glucose monitors that require a finger prick, diabetics on the Libre spent 38% less time in hypoglycemia, the company said. Patients in the clinical […]
Report: Abbott audits Alere’s books ahead of $6B merger
Abbott (NYSE:ABT) reportedly triggered its right to audit Alere‘s (NYSE:ALR) books before consummating their $5.8 billion merger. “Abbott is abiding by the terms of the contract with Alere and has exercised its contractual rights to audit Alere’s books and records,” spokeswoman Darcy Ross told Bloomberg. “To date, we have had a partial response from the company.” Alere said it […]
Abbott warns on Topera catheter spline fracture risk
The electrophysiology business Abbott (NYSE:ABT) built around its $250 million acquisition of Topera Medical this month warned physicians about the risk that the splines on some of its Firmap catheters could fracture. Abbott EP said it received 16 reports of catheter spline fracture from October 2013 to April 18, for an incidence rate of less than 0.4%. There […]
Abbott’s Tecnis Symfony intraocular lens clears pivotal trial
Abbott (NYSE:ABT) said today its Tecnis Symfony 1-piece acrylic intraocular lens met its primary endpoint in the pivotal trial of the device designed for cataract surgery. Data from the trial indicated that people who were implanted with the lens demonstrated improved intermediate and near vision compared to those who received a monofocal intraocular lens, the company […]
Abbott deal for St. Jude Medical continues consolidation trend
The acquisition of St. Jude Medical (NYSE:STJ) by Abbott (NYSE:ABT) continues the trend toward consolidation among large medtech companies, even as it necessarily means big-name targets are more difficult to find. The $25 billion offer is the 2nd big deal for Abbott in the past few months; in February, the Chicago-area health products giant announced the $5.89 billion buyout […]
Abbott + St. Jude Medical: What does it mean for med tech innovators?
By Amy Siegel, S2N Health We awoke yesterday to news of yet another med tech mega-merger, with acquisitive Abbott ponying up $25B for St. Jude Medical, even before the ink is dry on Abbott’s $6B takeover of Alere (though that deal may be on the rocks). Fair to say that consolidation in med tech is firmly […]
Alere rejected Abbott’s $50m offer to spike merger
Alere (NYSE:ALR) said yesterday that it rejected an offer from Abbott (NYSE:ABT) to pay up to $50 million to spike their pending, $5.8 billion merger, even as news broke of Abbott’s $25 billion bid for St. Jude Medical (NYSE:STJ). The Chicago-area healthcare giant’s nearly $6 billion acquisition of Alere, the Waltham, Mass.-based diagnostics firm drew scrutiny after Abbott CEO Miles […]
Abbott to pay $25B for St. Jude Medical
Abbott (NYSE:ABT) said today that it offered to pay a 37% premium for St. Jude Medical (NYSE:STJ) in a $25 billion deal aimed at expanding its cardiac and neurological businesses. Each unit in the $85-per-share deal consists of $46.75 in cash and 0.8708 ABT shares; at Abbott’s 5-day volume weighted average share price of $43.93 as of April 26, the buyout is […]
Flex taps ex J&J med device R&D exec Carlson for Flex Med Solutions prez | Personnel Moves April 26, 2016
Flex taps ex J&J med device R&D exec Carlson for Flex Med Solutions prez Flex (NSDQ:FLEX) said it hired ex-Johnson & Johnson (NYSE:JNJ) innovation portfolio veep as its new president of Flex Medical solutions. The position will put Carlson in charge of the company’s $8 billion research & development budget across pharmaceuticals, medical devices and consumer […]
Shareholders sue Alere to block Abbott buyout
(Reuters) – Diagnostics company Alere (NYSE:ALR) has been hit with a securities fraud lawsuit accusing it of artificially inflating its share prices ahead of the Feb. 1 announcement of its proposed $5.8 billion acquisition by Abbott (NYSE:ABT). The shareholder lawsuit, filed on Thursday in federal court in Boston, accused Alere of misleading investors by stating that […]